Revenue expansion was led by a substantial 34.5% surge in international business alongside steady double-digit gains in domestic operations. Key domestic segments including women's health, cardio-metabolics, and central nervous system therapies supported growth through top-performing brands like Orofer XT and Rosuvas EZ. Operating profitability also strengthened significantly, with EBITDA margins expanding by 103 basis points to reach 20.4%.
Key points
Expanding global distribution and key therapies such as Liposomal Amphotericin B are subs…: Expanding global distribution and key therapies such as Liposomal Amphotericin B are substantially driving international revenue performance.
Operational restructuring through the planned merger of Zuventus and Emcutix aims to unlo…: Operational restructuring through the planned merger of Zuventus and Emcutix aims to unlock functional efficiencies under the One Emcure initiative.
Domestic franchise strength relies heavily on expanding market traction across women's he…: Domestic franchise strength relies heavily on expanding market traction across women's health, cardio-metabolics, and central nervous system portfolios.
Sources checked by our analysis pipeline: 1
The stock pared some gains thereafter but continued to trade higher.
Emcure Pharma Q2 results
The company's adjusted PAT rose to Rs 325.1 crore in Q2FY27, up from Rs 251.4 crore reported in the corresponding quarter of the previous financial year.
Revenue from operations increased 24.3% YoY to Rs 2,820.5 crore during the quarter, from Rs 2,269.8 crore in Q2FY26.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 30.9% YoY to Rs 574.8 crore, compared with Rs 439.1 crore in the year-ago quarter. EBITDA margin improved by 103 basis points to 20.4%, from 19.3% in Q2FY26.
ALSO READ: Nifty's Diwali-to-Diwali slide: Will year-end gains light up Dalal Street?
Domestic business
Domestic revenue increased 12% YoY to Rs 1,155.3 crore during the quarter, compared with Rs 1,031.4 crore in the corresponding period last year.
The company reported double-digit YoY growth in its domestic business for the second consecutive quarter, with growth improving from 10% in Q1FY27 to 12% in Q2FY27.
Growth during the quarter was led by the women's health, cardio-metabolics and central nervous system (CNS) segments.
Guangzhou Automobile Group's battery division, INPOW, has commenced operations at a new manufacturing site in Chonburi province to build electric vehicle packs. The initiative aims to fortify regional supply-chain security and accelerate vehicle deliveries as the company deepens its presence across Southeast Asia. By pairing core component assembly directly with vehicle production, the automaker is working to substantially reduce its dependence on Chinese export logistics.
The fast-food chain is grappling with deeper customer cutbacks across its locations following recent health concerns. Financial results show the resulting downturn has surpassed internal and industry projections, complicating short-term revenue expectations. Leadership now faces the challenge of stabilizing foot traffic to curb ongoing losses.